Icecure Medical LTD F-1 registration statements

IceCure Medical Ltd. has filed an F-1 registration statement for the resale of up to 16 million ordinary shares by selling shareholders, stemming from recent warrant issuances.

IceCure Medical Ltd. has initiated a non-transferable rights offering aiming to raise up to $10 million, primarily to repay a bridge loan and for general corporate purposes, while reporting anticipated lower product sales and higher net loss for the first half of 2025 due to regional conflict.

IceCure Medical Ltd. is conducting a non-transferable rights offering to raise up to $10 million, primarily to repay a bridge loan and fund operations through May 2026, while facing a delayed FDA marketing authorization for its ProSense system and ongoing geopolitical instability in Israel.

IceCure Medical Ltd. has filed an amended F-1 registration statement for a non-transferable rights offering aiming to raise up to $10 million to fund operations and repay a bridge loan, while navigating a delayed FDA marketing authorization for its ProSense system and regional geopolitical risks.

IceCure Medical Ltd. has filed an F-1 registration statement for a non-transferable rights offering aiming to raise up to $10 million to repay a bridge loan and support general corporate and working capital needs, while awaiting final FDA marketing authorization for its ProSense system.

IceCure Medical Ltd. is launching a best efforts offering of up to 22,222,222 ordinary shares and warrants, aiming to raise approximately $16.5 million for business development, R&D, and general corporate purposes.

IceCure Medical Ltd. aims to raise capital by offering ordinary shares, pre-funded warrants, and accompanying warrants, with proceeds intended for business development, marketing, and R&D.

IceCure Medical Ltd. is offering ordinary shares and warrants in a best efforts offering to fund business development, R&D, and general corporate purposes.